Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2013-03-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
七届二次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of Kunming Pharmaceutical Group Co., Ltd. regarding the resolutions passed at their second supervisory board meeting of the seventh session. It includes approval of the 2012 supervisory board work report, the 2012 financial settlement report, and the 2012 annual report and its summary. Additionally, it contains the supervisory board's independent opinion on the 2012 annual report, confirming compliance with relevant laws, regulations, and stock exchange requirements. The document is relatively short (880 characters) and serves as an official announcement of the supervisory board's review and approval of the annual report rather than the full annual report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement related to the annual report but does not contain the full report or detailed financial statements.
2013-03-11 Chinese
2012年度社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled '2012 年度社会责任报告' which translates to '2012 Annual Social Responsibility Report'. The content focuses extensively on the company's social responsibility initiatives, environmental protection, employee welfare, governance improvements, and community engagement. There is no indication that this is a financial report like an Annual Report (10-K) or Interim Report (IR). It is not a brief announcement or a certification, nor does it relate to governance structure changes or legal proceedings. The document fits the description of an Environmental & Social Information report, detailing the company's performance on Environmental, Social, and Governance (ESG) factors. The document length (6249 characters) supports it being a full report rather than a brief announcement.
2013-03-11 Chinese
2013年日常关联交易预估公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's estimated related party transactions for the year 2013. It includes transaction categories, counterparties, estimated amounts, descriptions of related parties, pricing policies, impact analysis, board meeting resolutions, and independent directors' opinions. The document is a formal announcement of expected related party transactions, which is a regulatory disclosure typically required by stock exchanges to inform shareholders and the market about ongoing or anticipated related party dealings. It is not a financial report like an annual or interim report, nor is it a management discussion or earnings release. It is also not a proxy statement, voting result, or legal proceeding. The document is longer than 5,000 characters and contains substantive content about related party transactions, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2013-03-11 Chinese
关于召开2012年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice for the 2012 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd., detailing the meeting time, location, agenda items for shareholder voting, and instructions for both physical and online voting. It includes information about the shareholder meeting logistics, voting procedures, and proxy authorization forms. There is no financial data or report content itself, but rather an announcement about the upcoming AGM and its arrangements. The document length is 4091 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2013-03-11 Chinese
对外担保公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding an external guarantee provided by the company for its wholly-owned subsidiary. It details the guarantee amount, the subsidiary's financial status, the board's approval, and the requirement for shareholder meeting approval due to the guarantee size. The document is short (1287 characters) and focuses on a specific financing-related guarantee event rather than a full financial report or earnings release. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or management report. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company.
2013-03-11 Chinese
2012年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2012年度内部控制自我评价报告" which translates to "2012 Annual Internal Control Self-Evaluation Report". It is issued by the board of directors and includes detailed descriptions of the company's internal control systems, risk assessments, control procedures, and evaluation results for the fiscal year ending December 31, 2012. The document is comprehensive, covering internal control design and operational effectiveness, and includes a formal statement from the board chairman. It is not an announcement or a brief summary but a full report on internal control evaluation. This type of document aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and compliance with regulatory standards, rather than a full annual report (10-K) or other categories. The length (over 10,000 characters) and detailed content confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2012
2013-03-11 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.